Abstract
Adenosine-to-Inosine RNA editing introduces changes in RNA transcripts via a post-transcriptional mechanism, the hydrolytic deamination of adenosine (A) to inosine (I) which is interpreted as guanosine by cellular machineries. Adenosine deaminases that act on RNA (ADAR) enzymes catalyze editing in double-stranded (ds) RNA substrates.
Keywords: Adenosine, inosine, RNA, editing, drosophila, ion channel, convergence
Mini-Reviews in Medicinal Chemistry
Title: Adenosine-to-Inosine RNA Editing: Perspectives and Predictions
Volume: 6 Issue: 11
Author(s): Barry Hoopengardner
Affiliation:
Keywords: Adenosine, inosine, RNA, editing, drosophila, ion channel, convergence
Abstract: Adenosine-to-Inosine RNA editing introduces changes in RNA transcripts via a post-transcriptional mechanism, the hydrolytic deamination of adenosine (A) to inosine (I) which is interpreted as guanosine by cellular machineries. Adenosine deaminases that act on RNA (ADAR) enzymes catalyze editing in double-stranded (ds) RNA substrates.
Export Options
About this article
Cite this article as:
Hoopengardner Barry, Adenosine-to-Inosine RNA Editing: Perspectives and Predictions, Mini-Reviews in Medicinal Chemistry 2006; 6 (11) . https://dx.doi.org/10.2174/138955706778742812
DOI https://dx.doi.org/10.2174/138955706778742812 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research Commentary [ Research Highlights(To miR or Not to miR: That is the Question in ALS Disease ]
CNS & Neurological Disorders - Drug Targets Heat Shock Proteins Protect Against Ischemia and Inflammation Through Multiple Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer’s Disease
Current Pharmaceutical Design Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Non-Viral Methods For Generating Integration-Free, Induced Pluripotent Stem Cells
Current Stem Cell Research & Therapy Metallothionein I+II Expression as an Early Sign of Chronic Relapsing Experimental Autoimmune Encephalomyelitis in Rats
Current Aging Science Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology Glutamate-Mediated Signaling and Autism Spectrum Disorders: Emerging Treatment Targets
Current Pharmaceutical Design The Proteasome in Health and Disease
Current Pharmaceutical Design Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine